Plasma Fractionation Market by Product (Immunoglobulins [Intravenous, Subcutaneous], Albumin, Protease Inhibitors, VWF), Application (Preclinical, Therapeutics), Therapy (Neurology, Immunology, Hematology, Rheumatology), Region - Global Forecast to 2031

icon1
USD 52.58 BN
MARKET SIZE, 2031
icon2
CAGR 7.6%
(2026-2031)
icon3
400
REPORT PAGES
icon4
450
MARKET TABLES

OVERVIEW

plasma-fractionation-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The plasma fractionation market is projected to reach USD 52.58 billion by 2031, up from USD 36.44 billion in 2026, reflecting a 7.6% CAGR from 2026 to 2031. Market growth is driven by rising demand for immunoglobulins across immunology and neurology, strategic expansion of plasma collection capacity, and increased use of plasma-derived therapies. The growing use of immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma-derived products across therapeutic applications is accelerating demand for plasma fractionation and downstream manufacturing. Additionally, a growing focus on improving plasma utilization, protein recovery, product purity, and manufacturing efficiency is boosting demand for advanced fractionation, chromatography, filtration, and automated processing technologies across the market.

KEY TAKEAWAYS

  • By Region
    North America accounted for the largest share of 45.5% of the plasma fractionation market in 2025.
  • By Product
    By product, immunoglobulins accounted for the largest share of 51.1% of the plasma fractionation market in 2025.
  • By Therapeutic Area
    By therapeutic area, neurology accounted for the largest share of the plasma fractionation market in 2025.
  • By Application
    By application, therapeutics accounted for 95.0% of the plasma fractionation market in 2025.
  • Competitive Landscape - Key Players
    CSL, Grifols, S.A., Takeda Pharmaceutical Company Limited, Octapharma AG, and Kedrion S.p.A. were identified as some of the star players in the plasma fractionation market, given their strong market share and product footprint.
  • Competitive Landscape - Startups
    SK Plasma , Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Kamada Pharmaceuticals among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The plasma fractionation market is expanding due to rising demand for plasma-derived therapies, increased use of immunoglobulins in immunology and neurology, expanded plasma collection capacity, and investments in fractionation and manufacturing infrastructure. Advances in plasma collection, fractionation, purification, and automated processing are also improving plasma utilization, protein recovery, and manufacturing efficiency.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The plasma fractionation market is shifting from conventional workflows to advanced, automated, high-throughput platforms that improve yield, purity, safety, and process reproducibility. Adoption of chromatography, optimized cold ethanol fractionation, depth filtration, centrifugation, and advanced downstream purification technologies is rising, enabling efficient recovery of immunoglobulins, albumin, coagulation factors, protease inhibitors, and other plasma proteins from complex plasma pools. Growing demand for scalable, resource-efficient workflows, supported by automation, continuous processing, single-use technologies, and advanced process monitoring, is accelerating market growth. Additionally, enhanced protein recovery, improved plasma utilization, reduced process variability, and greater integration of fractionation with downstream manufacturing are driving advances in this market.

plasma-fractionation-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Growing demand for immunoglobulins across immunology and neurology
  • Strategic expansion of plasma collection capacity by market players
RESTRAINTS
Impact
Level
  • High treatment costs and reimbursement constraints for plasma-derived products
  • Market disruption caused by recombinant alternatives
OPPORTUNITIES
Impact
Level
  • Government strategies for increasing regional self-sufficiency in plasma fractionation
CHALLENGES
Impact
Level
  • Stringent government regulations for maintaining safety and quality of plasma-derived products

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing demand for immunoglobulins across immunology and neurology

The growing demand for immunoglobulins is strengthening the plasma fractionation market by increasing the need for IVIG, SCIG, and other immunoglobulins used to treat immunological and neurological conditions. Rising prevalence and diagnosis of primary immunodeficiencies, autoimmune disorders, CIDP, and Guillain-Barré syndrome, along with recurring treatment requirements, are supporting demand. Investments in plasma collection and fractionation capacity are further helping market players meet growing therapeutic needs.

Restraint: High treatment costs and reimbursement constraints for plasma-derived products

High treatment costs remain a major barrier, particularly for plasma-derived products that require repeated or long-term administration. Costs for plasma collection, testing, fractionation, purification, and quality control contribute to overall product prices. Limited reimbursement coverage, differences in healthcare payment systems, and affordability constraints can restrict patient access and adoption, particularly in emerging markets.

Opportunity: Government strategies for increasing regional self-sufficiency in plasma fractionation

Government initiatives to increase regional self-sufficiency create opportunities by encouraging domestic plasma collection, fractionation, and manufacturing infrastructure. Investments in plasma collection networks, donor recruitment, fractionation facilities, and local manufacturing can improve supply security and reduce reliance on imported plasma-derived products. Companies with integrated collection and manufacturing capabilities are well positioned to benefit from these initiatives.

Challenge: Stringent government regulations for maintaining safety and quality of plasma-derived products

Stringent regulatory requirements pose challenges across plasma collection, donor screening, infectious disease testing, traceability, fractionation, viral safety, and product manufacturing. Extensive validation, quality testing, documentation, and batch-release requirements increase compliance complexity and costs. Differences in regulatory requirements across countries can further complicate manufacturing and market expansion while maintaining consistent product quality and safety.

PLASMA FRACTIONATION MARKET SIZE, GROWTH, SHARE & TRENDS ANALYSIS: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
 Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
 Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The plasma fractionation market ecosystem comprises plasma collection organizations, plasma fractionators and plasma-derived product manufacturers, healthcare providers and end users, and regulatory and standards organizations. Plasma collection organizations support the market by providing source plasma through plasmapheresis, donor screening, infectious disease testing, storage, and traceability. Plasma fractionators and product manufacturers, including CSL, Takeda, Grifols, Octapharma, and Kedrion, provide fractionation, purification, and manufacturing capabilities for immunoglobulins, albumin, coagulation factor concentrates, protease inhibitors, and other plasma-derived products. Regulatory authorities, including the US FDA, EMA, MHRA, CDSCO, PMDA, and NMPA, establish requirements for plasma collection, product safety and quality, traceability, and manufacturing compliance. End users, including hospitals and specialty clinics, home care settings and infusion centers, academic institutions, and clinical research laboratories, use plasma-derived products across immunology, neurology, hematology, critical care, pulmonology, hemato-oncology, and rheumatology applications.

plasma-fractionation-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

plasma-fractionation-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Plasma Fractionation Market, By Product

In 2025, the immunoglobulins segment dominated the plasma fractionation market, driven by the ongoing use of IVIG, SCIG, and other immunoglobulins for primary immunodeficiencies, autoimmune disorders, and neurological conditions. Rising diagnosis of immune-mediated diseases, increasing clinical adoption of immunoglobulin therapies, and long-term treatment requirements continue to support demand. Expanding plasma collection and fractionation capacity is further supporting a reliable supply of immunoglobulin products across major healthcare markets.

Plasma Fractionation Market, By Application

In 2025, the therapeutics segment dominated the plasma fractionation market, supported by the widespread clinical use of plasma-derived products across immunology, neurology, hematology, critical care, pulmonology, and other therapeutic areas. Growing demand for immunoglobulins, coagulation factor concentrates, albumin, and protease inhibitors is driving the use of plasma-derived products in therapeutic applications. Rising disease prevalence and recurring treatment requirements are further strengthening demand for plasma-derived therapies.

Plasma Fractionation Market, By End User

In 2025, hospitals & specialty clinics dominated the plasma fractionation market, driven by the extensive use of plasma-derived products in settings requiring physician supervision, infusion support, and clinical monitoring. These facilities are major users of immunoglobulins, coagulation factor concentrates, albumin, and other plasma-derived products across neurological, immunological, hematological, and critical-care applications. Established healthcare infrastructure and increasing use of plasma-derived therapies further support the leading position of hospitals and specialty clinics.

REGION

Asia Pacific to be the largest market for battery as a service business model

Asia Pacific is projected to dominate the Battery as a Service market, supported by rapid EV adoption, across passenger cars, two wheelers, three wheelers, and commercial fleets. High vehicle utilization, sensitivity to upfront EV costs, and growing demand for flexible battery ownership models are supporting BaaS adoption across markets such as India, Indonesia, and China. The region also benefits from expanding EV financing ecosystems and increasing participation from automakers, battery companies, and financial service providers. Growing deployment of digital battery monitoring and usage based payment platforms is further improving the scalability of BaaS models.

plasma-fractionation-market Region

PLASMA FRACTIONATION MARKET SIZE, GROWTH, SHARE & TRENDS ANALYSIS: COMPANY EVALUATION MATRIX

In the plasma fractionation market company evaluation matrix, CSL (Australia) is positioned as a star player due to its strong presence across plasma collection, fractionation, and plasma-derived product manufacturing. Through CSL Behring and its integrated plasma collection network, the company offers a broad range of immunoglobulins, albumin, coagulation factor concentrates, and other plasma-derived therapies for immunology, neurology, hematology, and critical care applications. Its global reach, extensive plasma collection infrastructure, large-scale fractionation capabilities, and focus on manufacturing efficiency and automation strengthen its market position. The company is also expanding its plasma-derived therapy manufacturing capacity, including investments in the US, to meet rising demand and enhance regional supply capabilities. GC Biopharma Corporate (South Korea) is an emerging leader, supported by its plasma-derived product portfolio, established fractionation capabilities, and growing presence across Asian markets. Its continued investments in plasma collection, manufacturing infrastructure, and product development are expanding regional plasma-derived product supply and strengthening its position in the global plasma fractionation market.

plasma-fractionation-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 34.46 Billion
Market Size in 2026 (Value) USD 36.44 Billion
Market Forecast in 2031 (Value) USD 52.58 Billion
Growth Rate CAGR of 7.6% from 2026 to 2031
Years Considered 2024-2031
Base Year 2025
Forecast Period 2026-2031
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Product:
    • Immunoglobulins
    • Coagulation Factor Concentrates
    • Albumin
    • Protease Inhibitors
    • Other Plasma Products
  • By Application:
    • Therapeutics
    • Academics & Preclinical Research
  • By Therapeutic Area:
    • Neurology
    • Immunology
    • Hematology
    • Critical Care
    • Pulmonology
    • Hemato-Oncology
    • Rheumatology
    • Other Applications
  • By End User:
    • Hospitals & Specialty Clinics
    • Homecare Settings & Infusion Centers
    • Other End Users
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: PLASMA FRACTIONATION MARKET SIZE, GROWTH, SHARE & TRENDS ANALYSIS REPORT CONTENT GUIDE

plasma-fractionation-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Rest of Europe Breakdown Country-level market sizing and growth forecasts (Switzerland, Sweden, Turkey, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Finland, the Czech Republic, Greece, Austria, Belgium, and Russia) Provides granular country-level insights, enabling clients to prioritize high-growth markets
Company Evaluation
  • Detailed analysis and profiling of top five market players
  • Portfolio assessment of top five companies
 Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions

RECENT DEVELOPMENTS

  • March 2026 : CSL broke ground on a USD 1.5 billion expansion of its Kankakee, Illinois, plasma-therapy manufacturing facility. The project will increase production of plasma-derived therapies and albumin and introduce CSL's Horizon 2 process to improve immunoglobulin yield from the same volume of plasma. The expanded facility is expected to be operational by 2031.
  • June 2025 : Takeda received US FDA approval for GAMMAGARD LIQUID ERC, a ready-to-use 10% human immunoglobulin formulation with very low IgA content for the treatment of primary immunodeficiency. US commercialization was planned for 2026.
  • June 2026 : Grifols launched FESILTY in the US as a new fibrinogen concentrate for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency. The plasma-derived fibrinogen product expands Grifols' portfolio of plasma-derived coagulation therapies.

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
38
2
EXECUTIVE SUMMARY
 
 
 
 
 
42
3
PREMIUM INSIGHTS
 
 
 
 
 
48
4
MARKET OVERVIEW
Explore strategic expansions and opportunities in the booming plasma fractionation market amid rising demand.
 
 
 
 
 
51
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
GROWING DEMAND FOR IMMUNOGLOBULINS ACROSS IMMUNOLOGY AND NEUROLOGY
 
 
 
 
 
 
4.2.1.2
STRATEGIC EXPANSION OF PLASMA COLLECTION CAPACITY BY MARKET PLAYERS
 
 
 
 
 
 
 
 
4.2.1.2.1
PLASMA COLLECTION-BY VOLUME
 
 
 
 
4.2.1.3
GROWING PREVALENCE OF RESPIRATORY DISEASES AND ALPHA- 1 ANTITRYPSIN DEFICIENCY
 
 
 
 
 
 
4.2.1.4
INCREASING UTILIZATION OF ALBUMIN IN CRITICAL CARE
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
HIGH TREATMENT COSTS AND REIMBURSEMENT CONSTRAINTS FOR PLASMA-DERIVED PRODUCTS
 
 
 
 
 
 
4.2.2.2
MARKET DISRUPTION CAUSED BY RECOMBINANT ALTERNATIVES
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
GOVERNMENT STRATEGIES FOR INCREASING REGIONAL SELF-SUFFICIENCY IN PLASMA FRACTIONATION
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
STRINGENT GOVERNMENT REGULATIONS FOR MAINTAINING SAFETY AND QUALITY OF PLASMA-DERIVED PRODUCTS
 
 
 
 
4.3
UNMET NEEDS & WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
Navigate competitive forces and macroeconomic shifts to capitalize on emerging biopharma trends.
 
 
 
 
 
62
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
 
5.1.2
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.3
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.4
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.5
THREAT OF NEW ENTRANTS
 
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS & FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
 
 
 
 
 
 
5.2.4
TRENDS IN GLOBAL BIOPHARMA INDUSTRY
 
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
 
5.4.1
ROLE OF PLAYERS IN ECOSYSTEM
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023–2025
 
 
 
 
 
 
5.5.2
AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
 
 
 
 
 
5.6
TRADE ANALYSIS
 
 
 
 
 
 
 
 
5.6.1
IMPORT SCENARIO (HS CODE 3002.12)
 
 
 
 
 
 
5.6.2
EXPORT SCENARIO (HS CODE 3002.12)
 
 
 
 
 
5.7
KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
5.9
INVESTMENT & FUNDING SCENARIO
 
 
 
 
 
 
 
5.10
CASE STUDY ANALYSIS
 
 
 
 
 
 
 
5.10.1
UK APPROVES DOMESTIC PLASMA FOR FIVE ADDITIONAL PDMPS
 
 
 
 
 
 
5.10.2
TAKEDA'S INDONESIA COLLABORATION STRENGTHENS NATIONAL PDMP ECOSYSTEM
 
 
 
 
 
 
5.10.3
ADVANCED VIRAL INACTIVATION IMPROVES PLASMA-DERIVED PRODUCT MANUFACTURING
 
 
 
 
 
5.11
IMPACT OF 2025 US TARIFFS ON PLASMA FRACTIONATION MARKET
 
 
 
 
 
 
 
 
5.11.1
INTRODUCTION
 
 
 
 
 
 
5.11.2
KEY TARIFF RATES
 
 
 
 
 
 
5.11.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.11.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.11.4.1
US
 
 
 
 
 
 
5.11.4.2
EUROPE
 
 
 
 
 
 
5.11.4.3
ASIA PACIFIC
 
 
 
 
 
5.11.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.11.5.1
HOSPITALS & SPECIALTY CLINICS
 
 
 
 
 
 
5.11.5.2
HOMECARE SETTINGS & INFUSION CENTERS
 
 
 
 
 
 
5.11.5.3
OTHER END USERS
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven plasma fractionation innovations revolutionize efficiency, patent growth, and future market applications.
 
 
 
 
 
85
 
6.1
TECHNOLOGY ANALYSIS
 
 
 
 
 
 
 
6.1.1
KEY TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1.1
COHN’S COLD ETHANOL PLASMA FRACTIONATION
 
 
 
 
 
 
6.1.1.2
PLASMA FRACTIONATION BY CHROMATOGRAPHY
 
 
 
 
 
 
6.1.1.3
PLASMA SEPARATION BY CENTRIFUGATION
 
 
 
 
 
 
6.1.1.4
PLASMA SEPARATION BY DEPTH FILTRATION
 
 
 
 
 
6.1.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.1.2.1
FACILITATED SUBCUTANEOUS INFUSION SYSTEMS
 
 
 
 
 
 
6.1.2.2
LIQUID-STABLE HIGH-CONCENTRATION (20%) FORMULATIONS
 
 
 
 
 
 
6.1.2.3
SINGLE-USE BIOPROCESSING & CONTINUOUS CHROMATOGRAPHY
 
 
 
 
 
6.1.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.1.3.1
AI-DRIVEN ANALYTICS & SMART FRACTIONATION YIELD OPTIMIZATION
 
 
 
 
 
 
6.1.3.2
NEXT-GENERATION AUTOMATED PLASMAPHERESIS & SMART DONOR CENTER SYSTEMS
 
 
 
 
6.2
TECHNOLOGY ROADMAP
 
 
 
 
 
 
6.3
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.3.1
METHODOLOGY
 
 
 
 
 
 
6.3.2
NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
 
 
 
 
 
 
6.3.3
LIST OF KEY PATENTS
 
 
 
 
 
6.4
FUTURE APPLICATIONS
 
 
 
 
 
 
6.5
IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET
 
 
 
 
 
 
 
 
6.5.1
TOP USE CASES & MARKET POTENTIAL
 
 
 
 
 
 
6.5.2
BEST PRACTICES IN AI-ENABLED PLASMA FRACTIONATION WORKFLOWS
 
 
 
 
 
 
6.5.3
CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET
 
 
 
 
 
 
6.5.4
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
 
 
 
 
 
 
6.5.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES
 
 
 
 
7
SUSTAINABILITY & REGULATORY LANDSCAPE
Navigate global sustainability with insights into regional regulations and eco-certification impacts.
 
 
 
 
 
96
 
7.1
REGIONAL REGULATIONS & COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
 
 
 
 
7.1.2.1
NORTH AMERICA
 
 
 
 
 
 
7.1.2.2
EUROPE
 
 
 
 
 
 
7.1.2.3
ASIA PACIFIC
 
 
 
 
 
 
7.1.2.4
REST OF THE WORLD
 
 
 
 
7.2
SUSTAINABILITY INITIATIVES
 
 
 
 
 
 
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
 
 
 
 
 
 
7.4
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock customer insights: Navigate complex buying processes and unmet needs across diverse industries.
 
 
 
 
 
105
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.2.2
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
9
PLASMA FRACTIONATION MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Tons | 119 Data Tables
 
 
 
 
 
110
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
IMMUNOGLOBULINS
 
 
 
 
 
 
 
9.2.1
IVIG
 
 
 
 
 
 
 
9.2.1.1
EXPANDING CLINICAL INDICATIONS, RISING IMMUNE DISORDER DIAGNOSES, AND ADVANCES IN IVIG FORMULATIONS TO DRIVE MARKET GROWTH
 
 
 
 
 
9.2.2
SCIG
 
 
 
 
 
 
 
9.2.2.1
RISING PREFERENCE FOR HOME-BASED TREATMENT, EXPANDING NEUROLOGICAL INDICATIONS, AND PATIENT-FRIENDLY ADMINISTRATION TO DRIVE SCIG DEMAND
 
 
 
 
 
9.2.3
OTHER IMMUNOGLOBULINS
 
 
 
 
 
9.3
COAGULATION FACTOR CONCENTRATES
 
 
 
 
 
 
 
9.3.1
FACTOR VIII
 
 
 
 
 
 
 
9.3.1.1
IMPROVED HEMOPHILIA DIAGNOSIS AND RELIABLE PLASMA-DERIVED PRODUCT SUPPLY TO BOOST DEMAND FOR FACTOR VIII
 
 
 
 
 
9.3.2
FACTOR IX
 
 
 
 
 
 
 
9.3.2.1
HEMOPHILIA B DIAGNOSIS AND CONTINUED DEMAND FOR REPLACEMENT THERAPY TO SUPPORT FACTOR IX UTILIZATION
 
 
 
 
 
9.3.3
VON WILLEBRAND FACTOR
 
 
 
 
 
 
 
9.3.3.1
EXPANDED PEDIATRIC PROPHYLAXIS AND INCREASING ACCESS TO SPECIALIZED BLEEDING DISORDER CARE TO SUPPORT MARKET GROWTH
 
 
 
 
 
9.3.4
PROTHROMBIN COMPLEX CONCENTRATES (PCC)
 
 
 
 
 
 
 
9.3.4.1
RAPID ANTICOAGULATION REVERSAL AND RISING EMERGENCY-CARE REQUIREMENTS TO AID MARKET GROWTH
 
 
 
 
 
9.3.5
FIBRINOGEN CONCENTRATES
 
 
 
 
 
 
 
9.3.5.1
RISING DEMAND FOR TARGETED COAGULATION REPLACEMENT TO DRIVE GLOBAL MARKET GROWTH
 
 
 
 
 
9.3.6
FACTOR XIII
 
 
 
 
 
 
 
9.3.6.1
GROWING DEMAND FOR PREVENTIVE REPLACEMENT THERAPY TO SUPPORT MARKET GROWTH
 
 
 
 
 
9.3.7
OTHER COAGULATION FACTOR CONCENTRATES
 
 
 
 
 
9.4
ALBUMIN
 
 
 
 
 
 
 
9.4.1
RISING DEMAND FOR CRITICAL CARE AND LIVER DISEASE THERAPIES TO BOOST MARKET GROWTH
 
 
 
 
 
9.5
PROTEASE INHIBITORS
 
 
 
 
 
 
 
9.5.1
INCREASING AATD DIAGNOSIS AND DEMAND FOR LONG-TERM AUGMENTATION THERAPY TO PROPEL MARKET
 
 
 
 
 
9.6
OTHER PLASMA PRODUCTS
 
 
 
 
 
10
PLASMA FRACTIONATION MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 15 Data Tables
 
 
 
 
 
165
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
THERAPEUTICS
 
 
 
 
 
 
 
10.2.1
STRONG CLINICAL DEMAND FOR PLASMA-DERIVED THERAPIES TO SUSTAIN THERAPEUTICS AS CORE APPLICATION OF PLASMA FRACTIONATION MARKET
 
 
 
 
 
10.3
ACADEMICS & PRECLINICAL RESEARCH
 
 
 
 
 
 
 
10.3.1
EXPANDING USE OF HUMAN PLASMA FRACTIONS IN RESEARCH AND BIOPROCESSING TO SUPPORT DEMAND
 
 
 
 
11
PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 57 Data Tables
 
 
 
 
 
174
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
NEUROLOGY
 
 
 
 
 
 
 
11.2.1
GROWING UTILIZATION OF PLASMA-DERIVED IMMUNOGLOBULINS IN NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR PLASMA FRACTIONATION
 
 
 
 
 
11.3
IMMUNOLOGY
 
 
 
 
 
 
 
11.3.1
INCREASING PREVALENCE OF IMMUNODEFICIENCIES AND AUTOIMMUNE DISORDERS TO DRIVE DEMAND FOR PLASMA-DERIVED IMMUNOGLOBULINS
 
 
 
 
 
11.4
HEMATOLOGY
 
 
 
 
 
 
 
11.4.1
RISING DEMAND FOR PLASMA-DERIVED COAGULATION FACTORS TO SUPPORT TREATMENT OF BLEEDING DISORDERS
 
 
 
 
 
11.5
CRITICAL CARE
 
 
 
 
 
 
 
11.5.1
ESSENTIAL DEMAND FOR ALBUMIN EXPANDERS AND FOUR-FACTOR CONCENTRATE REVERSAL AGENTS TO DRIVE CLINICAL UTILITY IN EMERGENCY SETTINGS
 
 
 
 
 
11.6
PULMONOLOGY
 
 
 
 
 
 
 
11.6.1
GROWING DIAGNOSIS OF ALPHA-1 ANTITRYPSIN DEFICIENCY TO SUPPORT DEMAND FOR PLASMA-DERIVED PROTEASE INHIBITORS
 
 
 
 
 
11.7
HEMATO-ONCOLOGY
 
 
 
 
 
 
 
11.7.1
INCREASING SUPPORTIVE-CARE REQUIREMENTS IN HEMATOLOGICAL MALIGNANCIES TO SUPPORT UTILIZATION OF PLASMA-DERIVED PRODUCTS
 
 
 
 
 
11.8
RHEUMATOLOGY
 
 
 
 
 
 
 
11.8.1
EXPANDING USE OF IMMUNOGLOBULIN THERAPY IN IMMUNE-MEDIATED DISORDERS TO SUPPORT DEMAND FOR PLASMA-DERIVED PRODUCTS
 
 
 
 
 
11.9
OTHER THERAPEUTIC AREAS
 
 
 
 
 
12
PLASMA FRACTIONATION MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
 
 
 
 
 
203
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
HOSPITALS & SPECIALTY CLINICS
 
 
 
 
 
 
 
12.2.1
INCREASING UTILIZATION OF PLASMA-DERIVED THERAPIES ACROSS CLINICAL TREATMENT SETTINGS TO DRIVE DEMAND FOR PLASMA FRACTIONATION PRODUCTS
 
 
 
 
 
12.3
HOME CARE SETTINGS & INFUSION CENTERS
 
 
 
 
 
 
 
12.3.1
GROWING ADOPTION OF HOME-BASED IMMUNOGLOBULIN ADMINISTRATION TO SUPPORT DEMAND FOR PLASMA-DERIVED THERAPIES
 
 
 
 
 
12.4
OTHER END USERS
 
 
 
 
 
13
PLASMA FRACTIONATION MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 21 Countries | 205 Data Tables.
 
 
 
 
 
214
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
NORTH AMERICA
 
 
 
 
 
 
 
13.2.1
US
 
 
 
 
 
 
 
13.2.1.1
EXPANDING PLASMA COLLECTION, FRACTIONATION CAPACITY, AND IMMUNOGLOBULIN DEMAND TO DRIVE US MARKET GROWTH
 
 
 
 
 
13.2.2
CANADA
 
 
 
 
 
 
 
13.2.2.1
RISING IMMUNOGLOBULIN DEMAND AND INVESTMENTS IN DOMESTIC PLASMA SUPPLY TO DRIVE MARKET GROWTH
 
 
 
 
13.3
EUROPE
 
 
 
 
 
 
 
13.3.1
GERMANY
 
 
 
 
 
 
 
13.3.1.1
EXPANDING PLASMA COLLECTION INFRASTRUCTURE AND RISING DEMAND FOR PLASMA-DERIVED THERAPIES TO DRIVE MARKET GROWTH IN GERMANY
 
 
 
 
 
13.3.2
UK
 
 
 
 
 
 
 
13.3.2.1
RISING IMMUNOGLOBULIN DEMAND, DOMESTIC PLASMA COLLECTION, AND INVESTMENTS IN FRACTIONATION CAPACITY TO BOOST MARKET GROWTH
 
 
 
 
 
13.3.3
FRANCE
 
 
 
 
 
 
 
13.3.3.1
ESTABLISHED HEALTHCARE INFRASTRUCTURE AND PUBLIC PLASMA DONATION MODEL TO SUPPORT ACCESS TO TREATMENT
 
 
 
 
 
13.3.4
ITALY
 
 
 
 
 
 
 
13.3.4.1
GROWING USE OF IMMUNOGLOBULINS FOR NEUROLOGICAL AND IMMUNOLOGICAL DISORDERS TO DRIVE DEMAND
 
 
 
 
 
13.3.5
SPAIN
 
 
 
 
 
 
 
13.3.5.1
GROWING UTILIZATION OF ALBUMIN FOR CRITICAL CARE AND COAGULATION FACTOR CONCENTRATES FOR BLEEDING DISORDERS TO SUPPORT GROWTH
 
 
 
 
 
13.3.6
REST OF EUROPE
 
 
 
 
 
13.4
ASIA PACIFIC
 
 
 
 
 
 
 
13.4.1
CHINA
 
 
 
 
 
 
 
13.4.1.1
LARGE DOMESTIC DONOR-PLASMA COLLECTION NETWORK AND MANUFACTURERS FOCUSED ON EXPANDING PRODUCT AVAILABILITY TO DRIVE GROWTH
 
 
 
 
 
13.4.2
JAPAN
 
 
 
 
 
 
 
13.4.2.1
HIGHLY ORGANIZED BLOOD DONATION SYSTEM AND NATIONAL FOCUS ON SECURING PLASMA FOR DOMESTIC THERAPEUTIC REQUIREMENTS TO BOOST MARKET
 
 
 
 
 
13.4.3
INDIA
 
 
 
 
 
 
 
13.4.3.1
SUBSTANTIAL UNMET TREATMENT NEEDS AND EFFORTS TO IMPROVE ACCESS TO QUALITY-ASSURED PLASMA-DERIVED MEDICINES TO DRIVE GROWTH
 
 
 
 
 
13.4.4
SOUTH KOREA
 
 
 
 
 
 
 
13.4.4.1
DOMESTIC MANUFACTURING EXPERTISE WITH INVESTMENTS IN STORAGE INFRASTRUCTURE AND OVERSEAS CONTRACT MANUFACTURING TO EXPAND MARKET
 
 
 
 
 
13.4.5
AUSTRALIA
 
 
 
 
 
 
 
13.4.5.1
NATIONAL SELF-SUFFICIENCY POLICY LINKING LOCALLY COLLECTED PLASMA WITH DOMESTIC MANUFACTURING AND PATIENT SUPPLY TO POSITION AUSTRALIA AS MAJOR HUB
 
 
 
 
 
13.4.6
VIETNAM
 
 
 
 
 
 
 
13.4.6.1
IMPROVEMENTS IN HEALTHCARE ACCESS AND GROWING AWARENESS OF PLASMA-DERIVED THERAPIES TO SUPPORT DEMAND
 
 
 
 
 
13.4.7
MALAYSIA
 
 
 
 
 
 
 
13.4.7.1
DEPENDENCE ON IMPORTED PLASMA-DERIVED THERAPIES TO INCREASE FOCUS ON PLASMA COLLECTION, CONTRACT FRACTIONATION, AND LONG-TERM SUPPLY AGREEMENTS
 
 
 
 
 
13.4.8
INDONESIA
 
 
 
 
 
 
 
13.4.8.1
LARGE PATIENT POPULATION AND INCREASING DIAGNOSIS OF NEUROLOGICAL AND IMMUNOLOGICAL DISORDERS TO SUPPORT DEMAND FOR IMMUNOGLOBULINS
 
 
 
 
 
13.4.9
REST OF ASIA PACIFIC
 
 
 
 
 
13.5
LATIN AMERICA
 
 
 
 
 
 
 
13.5.1
BRAZIL
 
 
 
 
 
 
 
13.5.1.1
EXPANDING LOCAL PROCESSING TO CREATE OPPORTUNITIES TO IMPROVE PLASMA UTILIZATION AND STRENGTHEN BRAZIL'S BIOPHARMACEUTICAL SUPPLY CHAIN
 
 
 
 
 
13.5.2
MEXICO
 
 
 
 
 
 
 
13.5.2.1
BROADER NATIONAL STRATEGY TO EXPAND PHARMACEUTICAL MANUFACTURING AND REDUCE RELIANCE ON IMPORTED MEDICINES TO DRIVE MARKET
 
 
 
 
 
13.5.3
REST OF LATIN AMERICA
 
 
 
 
 
13.6
MIDDLE EAST
 
 
 
 
 
 
 
13.6.1
GCC COUNTRIES
 
 
 
 
 
 
 
13.6.1.1
SAUDI ARABIA
 
 
 
 
 
 
 
 
13.6.1.1.1
NATIONAL OBJECTIVE OF ACHIEVING SELF-SUFFICIENCY IN PLASMA-DERIVED MEDICINES AND REDUCING DEPENDENCE ON IMPORTED THERAPIES TO AID GROWTH
 
 
 
 
13.6.1.2
UAE
 
 
 
 
 
 
 
 
13.6.1.2.1
GROWING INVESTMENT IN PHARMACEUTICAL LOCALIZATION AND EFFORTS TO STRENGTHEN NATIONAL MEDICINE SECURITY TO BOOST GROWTH
 
 
 
 
13.6.1.3
REST OF GCC COUNTRIES
 
 
 
 
 
13.6.2
TURKEY
 
 
 
 
 
 
 
13.6.2.1
DOMESTIC FRACTIONATION INVESTMENT, IMPORT SUBSTITUTION, AND RISING DEMAND FOR PLASMA-DERIVED THERAPIES TO DRIVE GROWTH
 
 
 
 
 
13.6.3
EGYPT
 
 
 
 
 
 
 
13.6.3.1
DOMESTIC PLASMA SELF-SUFFICIENCY, EXPANDING COLLECTION INFRASTRUCTURE, AND INVESTMENT IN LOCAL FRACTIONATION TO FUEL MARKET
 
 
 
 
 
13.6.4
REST OF MIDDLE EAST
 
 
 
 
 
13.7
AFRICA
 
 
 
 
 
 
 
13.7.1
INVESTMENTS IN PLASMA COLLECTION, DOMESTIC MANUFACTURING, AND INTERNATIONAL PARTNERSHIPS TO SUPPORT DEVELOPMENT OF MARKET
 
 
 
 
14
COMPETITIVE LANDSCAPE
Discover strategic maneuvers propelling key players and startups in the plasma fractionation market.
 
 
 
 
 
318
 
14.1
OVERVIEW
 
 
 
 
 
 
14.2
KEY PLAYER STRATEGY/RIGHT TO WIN, 2023–2026
 
 
 
 
 
 
 
14.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023–AUGUST 2026
 
 
 
 
 
14.3
REVENUE ANALYSIS, 2021–2025
 
 
 
 
 
 
 
14.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
 
 
 
 
 
 
 
 
14.5.1
STARS
 
 
 
 
 
 
14.5.2
EMERGING LEADERS
 
 
 
 
 
 
14.5.3
PERVASIVE PLAYERS
 
 
 
 
 
 
14.5.4
PARTICIPANTS
 
 
 
 
 
 
14.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
 
 
 
 
 
 
 
14.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
14.5.5.2
REGION FOOTPRINT
 
 
 
 
 
 
14.5.5.3
PRODUCT FOOTPRINT
 
 
 
 
 
 
14.5.5.4
THERAPEUTIC AREA FOOTPRINT
 
 
 
 
 
 
14.5.5.5
APPLICATION FOOTPRINT
 
 
 
 
14.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
 
14.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
14.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
14.6.3
DYNAMIC COMPANIES
 
 
 
 
 
 
14.6.4
STARTING BLOCKS
 
 
 
 
 
 
14.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
14.6.5.1
DETAILED LIST OF KEY STARTUP/SME PLAYERS
 
 
 
 
 
 
14.6.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
14.7
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
 
 
14.7.1
COMPANY VALUATION
 
 
 
 
 
 
14.7.2
COMPANY VALUATION
 
 
 
 
 
14.8
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
 
14.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
14.9.1
PRODUCT LAUNCHES
 
 
 
 
 
 
14.9.2
DEALS
 
 
 
 
 
 
14.9.3
EXPANSIONS
 
 
 
 
15
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
340
 
15.1
KEY PLAYERS
 
 
 
 
 
 
 
15.1.1
CSL
 
 
 
 
 
 
 
15.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
15.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
15.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
15.1.1.3.1
PRODUCT LAUNCHES
 
 
 
 
 
 
15.1.1.3.2
EXPANSIONS
 
 
 
 
15.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
15.1.1.4.1
KEY STRENGTHS
 
 
 
 
 
 
15.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
15.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
 
 
 
15.1.2
GRIFOLS, S.A.
 
 
 
 
 
 
15.1.3
TAKEDA PHARMACEUTICAL COMPANY LIMITED
 
 
 
 
 
 
15.1.4
OCTAPHARMA AG
 
 
 
 
 
 
15.1.5
KEDRION S.P.A.
 
 
 
 
 
 
15.1.6
LFB
 
 
 
 
 
 
15.1.7
ADMA BIOLOGICS, INC.
 
 
 
 
 
 
15.1.8
SANQUIN
 
 
 
 
 
 
15.1.9
TAIBANG BIOLOGICAL GROUP CO., LTD.
 
 
 
 
 
 
15.1.10
GC BIOPHARMA CORPORATE
 
 
 
 
 
 
15.1.11
HUALAN BIOLOGICAL ENGINEERING INC.
 
 
 
 
 
 
15.1.12
JAPAN BLOOD PRODUCTS ORGANIZATION
 
 
 
 
 
 
15.1.13
EMERGENT
 
 
 
 
 
 
15.1.14
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
 
 
 
 
 
 
15.1.15
INTAS PHARMACEUTICALS LTD.
 
 
 
 
 
15.2
OTHER PLAYERS
 
 
 
 
 
 
 
15.2.1
BHARAT SERUMS AND VACCINES LIMITED
 
 
 
 
 
 
15.2.2
SK PLASMA
 
 
 
 
 
 
15.2.3
SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.
 
 
 
 
 
 
15.2.4
KAMADA PHARMACEUTICALS
 
 
 
 
 
 
15.2.5
CENTURION
 
 
 
 
 
 
15.2.6
PLASMAGEN BIOSCIENCES PVT. LTD.
 
 
 
 
 
 
15.2.7
VIRCHOW BIOTECH
 
 
 
 
 
 
15.2.8
FUSION HEALTHCARE
 
 
 
 
 
 
15.2.9
ICHOR
 
 
 
 
16
RESEARCH METHODOLOGY
 
 
 
 
 
399
 
16.1
RESEARCH DATA
 
 
 
 
 
 
 
16.1.1
SECONDARY DATA
 
 
 
 
 
 
 
16.1.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
16.1.2
PRIMARY DATA
 
 
 
 
 
 
 
16.1.2.1
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
 
 
16.1.2.2
KEY PRIMARY PARTICIPANTS
 
 
 
 
 
 
16.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
 
 
16.1.2.4
KEY INDUSTRY INSIGHTS
 
 
 
 
16.2
MARKET SIZE ESTIMATION
 
 
 
 
 
 
 
16.2.1
GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025
 
 
 
 
 
 
16.2.2
SEGMENTAL MARKET SIZE ESTIMATION
 
 
 
 
 
16.3
MARKET GROWTH RATE PROJECTIONS
 
 
 
 
 
 
16.4
DATA TRIANGULATION
 
 
 
 
 
 
16.5
FACTOR ANALYSIS
 
 
 
 
 
 
16.6
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
16.7
RESEARCH LIMITATIONS & RISK ASSESSMENT
 
 
 
 
 
17
APPENDIX
 
 
 
 
 
413
 
17.1
DISCUSSION GUIDE
 
 
 
 
 
 
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
17.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
17.4
RELATED REPORTS
 
 
 
 
 
 
17.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
PLASMA FRACTIONATION MARKET: INCLUSIONS & EXCLUSIONS
 
 
 
 
 
 
TABLE 2
PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
 
 
 
 
 
 
TABLE 3
NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2021–2022
 
 
 
 
 
 
TABLE 4
PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES
 
 
 
 
 
 
TABLE 5
PLASMA FRACTIONATION MARKET: ROLE OF PLAYERS IN ECOSYSTEM
 
 
 
 
 
 
TABLE 6
AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 7
AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 8
IMPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
 
 
 
 
 
 
TABLE 9
EXPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
 
 
 
 
 
 
TABLE 10
PLASMA FRACTIONATION MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–MARCH 2027
 
 
 
 
 
 
TABLE 11
RECIPROCAL TARIFF RATES ADJUSTED BY US
 
 
 
 
 
 
TABLE 12
CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
 
 
 
 
 
 
TABLE 13
NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025
 
 
 
 
 
 
TABLE 14
LIST OF KEY PATENTS IN PLASMA FRACTIONATION MARKET, 2023–2025
 
 
 
 
 
 
TABLE 15
CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET
 
 
 
 
 
 
TABLE 16
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES IN PLASMA FRACTIONATION MARKET
 
 
 
 
 
 
TABLE 17
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 18
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 19
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 20
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 21
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
 
 
 
 
 
 
TABLE 22
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
TABLE 23
PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 24
PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 25
PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 26
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 27
EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 28
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 29
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 30
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 31
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 32
PLASMA FRACTIONATION MARKET FOR IVIG, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 33
PLASMA FRACTIONATION MARKET FOR IVIG, 2024–2031 (METRIC TONS)
 
 
 
 
 
 
TABLE 34
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 35
EUROPE: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 38
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
PLASMA FRACTIONATION MARKET FOR SCIG, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
PLASMA FRACTIONATION MARKET FOR SCIG, 2024–2031 (METRIC TONS)
 
 
 
 
 
 
TABLE 42
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
EUROPE: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, 2024–2031 (METRIC TONS)
 
 
 
 
 
 
TABLE 50
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 56
PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 62
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 63
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
PLASMA FRACTIONATION MARKET FOR FACTOR VIII, 2024–2031 (MILLION IU)
 
 
 
 
 
 
TABLE 66
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 68
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 72
PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
PLASMA FRACTIONATION MARKET FOR FACTOR IX, 2024–2031 (MILLION IU)
 
 
 
 
 
 
TABLE 74
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
PLASMA FRACTIONATION MARKET FOR FACTOR VON WILLEBRAND FACTOR, 2024–2031 (MILLION LITER)
 
 
 
 
 
 
TABLE 82
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
EUROPE: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, 2024–2031 (MILLION IU)
 
 
 
 
 
 
TABLE 90
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
EUROPE: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, 2024–2031 (MILLION IU)
 
 
 
 
 
 
TABLE 98
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
EUROPE: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
PLASMA FRACTIONATION MARKET FOR FACTOR XIII, 2024–2031 (MILLION IU)
 
 
 
 
 
 
TABLE 106
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
PLASMA FRACTIONATION MARKET FOR ALBUMIN, 2024–2031 (METRIC TONS)
 
 
 
 
 
 
TABLE 121
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, 2024–2031 (MILLION IU)
 
 
 
 
 
 
TABLE 129
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 131
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 133
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 139
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
EUROPE: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 151
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
EUROPE: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 156
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 157
PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 163
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 165
PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 169
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 175
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 181
EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 185
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 187
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 191
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 193
PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 197
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 203
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 209
EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 210
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 211
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
EUROPE: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
PLASMA FRACTIONATION MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 239
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
US: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
US: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
US: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
US: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
CANADA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
CANADA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
CANADA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
EUROPE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
GERMANY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
GERMANY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
GERMANY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 268
GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
UK: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
UK: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
UK: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 274
UK: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
FRANCE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
FRANCE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 278
FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
FRANCE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 280
FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
ITALY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
ITALY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
ITALY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
ITALY: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
SPAIN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
SPAIN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
SPAIN: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
CHINA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 308
CHINA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
CHINA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
JAPAN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 314
JAPAN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
JAPAN: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
INDIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 320
INDIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 321
INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
INDIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
SOUTH KOREA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
SOUTH KOREA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 327
SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
AUSTRALIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
AUSTRALIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 333
AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
AUSTRALIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
VIETNAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
VIETNAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 339
VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
VIETNAM: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 342
MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
MALAYSIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
MALAYSIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 345
MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
MALAYSIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
INDONESIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
INDONESIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 351
INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
INDONESIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 357
REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 363
LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
BRAZIL: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
BRAZIL: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
BRAZIL: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 370
BRAZIL: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
BRAZIL: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
BRAZIL: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
MEXICO: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
MEXICO: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
MEXICO: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
MEXICO: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
MEXICO: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
MEXICO: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 394
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 395
GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 396
GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 397
GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 398
GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 399
SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 400
SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 401
SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 402
SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 403
SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 404
SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 405
UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 406
UAE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 407
UAE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 408
UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 409
UAE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 410
UAE: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 411
REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 412
REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 413
REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 414
REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 415
REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 416
REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 417
TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 418
TURKEY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 419
TURKEY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 420
TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 421
TURKEY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 422
TURKEY: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 423
EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 424
EGYPT: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 425
EGYPT: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 426
EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 427
EGYPT: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 428
EGYPT: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 429
REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 430
REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 431
REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 432
REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 433
REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 434
REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 435
AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 436
AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 437
AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 438
AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 439
AFRICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 440
AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 441
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 442
PLASMA FRACTIONATION MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 443
PLASMA FRACTIONATION MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 444
PLASMA FRACTIONATION MARKET: PRODUCT FOOTPRINT
 
 
 
 
 
 
TABLE 445
PLASMA FRACTIONATION MARKET: THERAPEUTIC AREA FOOTPRINT
 
 
 
 
 
 
TABLE 446
PLASMA FRACTIONATION MARKET: APPLICATION FOOTPRINT
 
 
 
 
 
 
TABLE 447
PLASMA FRACTIONATION MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 448
PLASMA FRACTIONATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 449
PLASMA FRACTIONATION MARKET: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 450
PLASMA FRACTIONATION MARKET: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 451
PLASMA FRACTIONATION MARKET: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 452
CSL: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 453
CSL: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 454
CSL: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 455
CSL: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 456
GRIFOLS, S.A.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 457
GRIFOLS, S.A.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 458
GRIFOLS, S.A.: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 459
GRIFOLS, S.A.: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 460
GRIFOLS, S.A.: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 461
TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 462
TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 463
TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 464
TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 465
TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 466
OCTAPHARMA AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 467
OCTAPHARMA AG: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 468
OCTAPHARMA AG: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 469
OCTAPHARMA AG: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 470
KEDRION S.P.A.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 471
KEDRION S.P.A.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 472
KEDRION S.P.A.: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 473
KEDRION S.P.A.: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 474
KEDRION S.P.A.: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 475
LFB: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 476
LFB: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 477
LFB: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 478
ADMA BIOLOGICS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 479
ADMA BIOLOGICS, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 480
ADMA BIOLOGICS, INC.: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 481
SANQUIN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 482
SANQUIN: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 483
SANQUIN: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 484
TAIBANG BIOLOGICAL GROUP CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 485
TAIBANG BIOLOGICAL GROUP CO., LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 486
TAIBANG BIOLOGICAL GROUP CO., LTD.: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 487
GC BIOPHARMA CORPORATE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 488
GC BIOPHARMA CORPORATE: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 489
GC BIOPHARMA CORPORATE: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 490
GC BIOPHARMA CORPORATE: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 491
GC BIOPHARMA CORPORATE: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 492
HUALAN BIOLOGICAL ENGINEERING INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 493
HUALAN BIOLOGICAL ENGINEERING INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 494
JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 495
JAPAN BLOOD PRODUCTS ORGANIZATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 496
JAPAN BLOOD PRODUCTS ORGANIZATION: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 497
JAPAN BLOOD PRODUCTS ORGANIZATION: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 498
EMERGENT: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 499
EMERGENT: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 500
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 501
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 502
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 503
INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 504
INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 505
INTAS PHARMACEUTICALS LTD.: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 506
INTAS PHARMACEUTICALS LTD.: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 507
BHARAT SERUMS AND VACCINES LIMITED: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 508
SK PLASMA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 509
SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 510
KAMADA PHARMACEUTICALS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 511
CENTURION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 512
PLASMAGEN BIOSCIENCES PVT. LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 513
VIRCHOW BIOTECH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 514
FUSION HEALTHCARE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 515
ICHOR: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 516
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
 
 
 
 
 
 
TABLE 517
RISK ASSESSMENT
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
PLASMA FRACTIONATION MARKET SEGMENTATION & REGIONS CONSIDERED
 
 
 
 
 
 
FIGURE 2
PLASMA FRACTIONATION MARKET: YEARS CONSIDERED
 
 
 
 
 
 
FIGURE 3
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 4
GLOBAL PLASMA FRACTIONATION MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 6
DISRUPTIONS INFLUENCING GROWTH OF PLASMA FRACTIONATION MARKET
 
 
 
 
 
 
FIGURE 7
HIGH-GROWTH SEGMENTS IN PLASMA FRACTIONATION MARKET, 2026–2031
 
 
 
 
 
 
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PLASMA FRACTIONATION MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 9
RISING ADOPTION OF PLASMA-DERIVED PRODUCTS IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH
 
 
 
 
 
 
FIGURE 10
THERAPEUTICS ACCOUNTED FOR LARGEST SHARE OF PLASMA FRACTIONATION MARKET IN NORTH AMERICA IN 2025
 
 
 
 
 
 
FIGURE 11
CHINA AND GERMANY LIKELY TO BE FASTEST-GROWING MARKETS IN GLOBAL PLASMA FRACTIONATION MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
THERAPEUTICS TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 13
PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 14
PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 15
PLASMA FRACTIONATION MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 16
PLASMA FRACTIONATION MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 17
AVERAGE SELLING PRICE OF PRODUCTS, 2025 (USD)
 
 
 
 
 
 
FIGURE 18
AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
 
 
 
 
 
 
FIGURE 19
PLASMA FRACTIONATION MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
FIGURE 20
INVESTMENT & FUNDING SCENARIO, 2024–2026 (USD MILLION)
 
 
 
 
 
 
FIGURE 21
PATENT APPLICATIONS IN PLASMA FRACTIONATION MARKET, JANUARY 2015–DECEMBER 2025
 
 
 
 
 
 
FIGURE 22
IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET
 
 
 
 
 
 
FIGURE 23
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
 
 
 
 
 
 
FIGURE 24
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
FIGURE 25
NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 26
ASIA PACIFIC: PLASMA FRACTIONATION MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 27
REVENUE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2021–2025 (USD MILLION)
 
 
 
 
 
 
FIGURE 28
MARKET SHARE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2025
 
 
 
 
 
 
FIGURE 29
PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 30
PLASMA FRACTIONATION MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 31
PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 32
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 33
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 34
PLASMA FRACTIONATION MARKET: BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
FIGURE 35
CSL: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 36
GRIFOLS, S.A.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 37
TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 38
OCTAPHARMA AG: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 39
KEDRION S.P.A.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 40
ADMA BIOLOGICS, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 41
SANQUIN: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 42
GC BIOPHARMA CORPORATE: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 43
EMERGENT: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 44
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 45
PLASMA FRACTIONATION MARKET: RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 46
PLASMA FRACTIONATION MARKET: BREAKDOWN OF PRIMARIES
 
 
 
 
 
 
FIGURE 47
PLASMA FRACTIONATION MARKET: INSIGHTS FROM PRIMARIES
 
 
 
 
 
 
FIGURE 48
GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025
 
 
 
 
 
 
FIGURE 49
PLASMA FRACTIONATION MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025)
 
 
 
 
 
 
FIGURE 50
ILLUSTRATIVE EXAMPLE OF CSL: REVENUE ANALYSIS (2025)
 
 
 
 
 
 
FIGURE 51
SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 52
PLASMA FRACTIONATION MARKET: CAGR PROJECTIONS
 
 
 
 
 
 
FIGURE 53
PLASMA FRACTIONATION MARKET: DATA TRIANGULATION
 
 
 
 
 
 

Methodology

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

Secondary Research

The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

Plasma Fractionation Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

Plasma Fractionation Market : Top-Down and Bottom-Up Approach

Plasma Fractionation Market Top Down and Bottom Up Approach

Data Triangulation

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

Market Definition

Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

Key Stakeholders

  • Plasma Fractionation Product Manufacturers and Distributors
  • Pharmaceutical and Biotechnology Companies
  • Healthcare Service Providers (including Hospitals and Clinics)
  • Research and Development (R&D) companies
  • Academic Institutes
  • Government Associations
  • Market Research and Consulting Firms
  • Venture Capitalists and Investors

Report Objectives

  • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
  • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
  • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

Available customizations:

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

Product Analysis

  • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
  • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
  • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
  • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Table of Contents

Methodology

 Request Customization Speak to Analyst
Speak to Analyst
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Plasma Fractionation Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Plasma Fractionation Market

avtar

Dr.

Feb, 2020

Informative; however, the study requires more details..

DMCA.com Protection Status
popup img